Daniel Spratt, MD, outlines the validation standards urologists should expect before adopting AI-based tools, where AI-driven digital pathology is headed, and his key takeaway from the benchmarking data.
Daniel Spratt, MD, explains how he layers MMAI results onto NCCN risk groups and how he manages discordant results in both directions.
Daniel Spratt, MD, reviews how closely MMAI-predicted 10-year distant metastasis and prostate cancer–specific mortality tracked observed STAR-CAP outcomes, including among patients treated with surgery.
Daniel Spratt, MD, explains what the STAR-CAP cohort is, what an MMAI risk estimate represents, and why calibration benchmarking differs from clinical validation.
Study design discussions can help patients weigh personalized marketing claims, according to Jean Cunningham, PharmD, BCPS.
Marie-Pier St-Laurent, MD, FRCSC, explains how NeoBLAST combines imaging, TURBT, and ctDNA to identify candidates for bladder-sparing surveillance.
Bladder symptoms during IVF often reflect hormonal and pelvic floor changes, not infection, according to Aleece Fosnight, MSPAS, PA-C.
Martin T. King, MD, PhD, looks ahead to micro-boost radiation, SBRT, and open questions about sexual and urinary quality of life that could reshape how rectal spacers are used.
No periprocedural adverse events and no new late safety signals: Martin T. King, MD, PhD, explains why 3-year data reassure him about rectal spacer use in appropriately selected patients.
Martin T. King, MD, PhD, compares his 3-year hyaluronic acid spacer results with prior hydrogel data and walks through the practical factors, sculpting, apical placement, reversibility, that shape his own product choice.
As IMRT and image-guided techniques push precision to its limits, Martin T. King, MD, PhD, argues rectal spacers still earn their place by widening the margin between prostate and rectum.
Rezūm improved symptoms and quality of life at 1 year vs combination pharmacotherapy in sexually active men with BPO while preserving sexual function.
Sri Sivalingam, MD, discusses how suction-based technologies are improving stone clearance and raising expectations for ureteroscopic stone treatment.
Martin T. King, MD, PhD, unpacks why fewer grade 2 or higher GI events with rectal spacing can mean fewer colonoscopies, less rectal bleeding, and meaningful quality-of-life gains for patients weighing their radiation options.
Martin T. King, MD, PhD, explains why his hypofractionated rectal spacer trial pushed for state-of-the-art radiotherapy in both arms, a design choice built to isolate the spacer's true clinical benefit.
Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
Mark D. Tyson, II, MD, MPH, reviews emerging bladder-sparing therapies for NMIBC, highlighting cretostimogene data, treatment sequencing, and the need for comparative trials.
An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.
Physiologic PSMA uptake in ganglia, ureters, and other normal structures can mimic disease, and the panel walks through the anatomic pitfalls that most often mislead inexperienced readers.
An indeterminate bone lesion forces clinicians to weigh pretest probability, tracer type, and biopsy risk before committing to a diagnosis, with serial scanning often settling the question over time.
Daniel Spratt, MD, outlines the limitations of PSA-, T stage-, and Gleason-based risk stratification and explains how AI-derived, continuous risk estimates could address them.
John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
Armine K. Smith, MD, discusses the importance of integrating sexual health into bladder cancer care, including proactive counseling, preservation strategies, and multidisciplinary support.
Radiotracer choice, cyclotron versus generator supply chains, and shifting reimbursement policy all shape which patients can access PSMA PET, according to two physicians who built imaging capacity directly into their practices.
Molecular imaging has displaced conventional CT and bone scans as the first-line staging tool in prostate cancer, but a radiation oncologist and a urologist explain where conventional imaging still holds value.
Sandip Prasad, MD, discusses patient selection for chemoablation in recurrent LG-IR-NMIBC and considerations when counseling patients about a nonsurgical approach.
Rahul Mehan, MD, explains when traditional resective procedures still make more sense than office-based options, shares his top advice for urologists early in adoption, and previews the minimally invasive technologies he's watching next.
Two years into offering drug-coated balloon dilation for BPH, Rahul Mehan, MD, compares his outcomes with the PINNACLE trial (NCT04131907), walks through sizing and patient selection, and details the recovery and safety counseling patients need before treatment.
Rahul Mehan, MD, explains why patients are pushing back on daily BPH medication, how prostate anatomy shapes the choice between mechanical, thermal, and drug-coated therapies, and what's fueling the shift to office-based care.
